EULAV Asset Management’s Edwards Lifesciences EW Stock Holding History

EULAV Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-113,010	Closed	-$12.8M	–	230
2021 Q3	$12.8M	Buy	+113,010	New	+$12.9M	0.34%	93
2021 Q2	–	Sell	-123,000	Closed	-$10.3M	–	226
2021 Q1	$10.3M	Sell	123,000 -7,000	-5%	-$592K	0.28%	105
2020 Q4	$11.9M	Sell	130,000 -6,000	-4%	-$498K	0.31%	102
2020 Q3	$10.9M	Buy	+136,000	New	+$10.6M	0.32%	97
2020 Q2	–	Sell	-114,000	Closed	-$7.17M	–	256
2020 Q1	$7.17M	Sell	114,000 -21,000	-16%	-$1.51M	0.29%	99
2019 Q4	$10.5M	Sell	135,000 -9,000	-6%	-$703K	0.36%	83
2019 Q3	$10.6M	Sell	144,000 -15,000	-9%	-$1.05M	0.39%	82
2019 Q2	$9.79M	Sell	159,000 -6,000	-4%	-$363K	0.37%	83
2019 Q1	$10.4M	Sell	165,000 -3,000	-2%	-$171K	0.43%	75
2018 Q4	$8.58M	Sell	168,000 -51,000	-23%	-$2.58M	0.43%	79
2018 Q3	$12.7M	Sell	219,000 -18,000	-8%	-$880K	0.54%	64
2018 Q2	$11.5M	Sell	237,000 -27,000	-10%	-$1.26M	0.53%	62
2018 Q1	$12.3M	Sell	264,000 -39,000	-13%	-$1.69M	0.59%	55
2017 Q4	$11.4M	Sell	303,000 -39,000	-11%	-$1.43M	0.54%	59
2017 Q3	$12.5M	Sell	342,000 -18,000	-5%	-$687K	0.59%	51
2017 Q2	$14.2M	Sell	360,000 -51,000	-12%	-$1.86M	0.7%	42
2017 Q1	$12.9M	Sell	411,000 -105,000	-20%	-$3.29M	0.66%	47
2016 Q4	$16.1M	Buy	516,000 +123,000	+31%	+$3.99M	0.87%	32
2016 Q3	$15.8M	Hold	393,000	–	–	0.84%	34
2016 Q2	$13.1M	Buy	393,000 +87,000	+28%	+$2.98M	0.72%	44
2016 Q1	$9M	Sell	306,000 -21,000	-6%	-$579K	0.5%	74
2015 Q4	$8.61M	Sell	327,000 -15,000	-4%	-$390K	0.47%	76
2015 Q3	$8.1M	Hold	342,000	–	–	0.46%	86
2015 Q2	$8.12M	Hold	342,000	–	–	0.43%	90
2015 Q1	$8.12M	Sell	342,000 -18,000	-5%	-$404K	0.42%	92
2014 Q4	$7.64M	Sell	360,000 -36,000	-9%	-$723K	0.41%	100
2014 Q3	$6.74M	Buy	396,000 +132,000	+50%	+$2.08M	0.37%	111
2014 Q2	$3.78M	Buy	+264,000	New	+$3.58M	0.2%	162
2014 Q1	–	Sell	-238,800	Closed	-$2.62M	–	400
2013 Q4	$2.62M	Sell	238,800 -102,000	-30%	-$1.15M	0.14%	212
2013 Q3	$3.96M	Sell	340,800 -213,600	-39%	-$2.5M	0.23%	156
2013 Q2	$6.21M	Buy	+554,400	New	+$6.56M	0.38%	92

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EULAV Asset Management's EW Position: Q4 2021 in Review

EULAV Asset Management sold out of Edwards Lifesciences (EW) in Q4 2021, closing a stake of 113,010 shares — an estimated $12.8M sold.

EULAV Asset Management first reported a position in EW in Q2 2013 and held it in 31 quarters. The position peaked at $16.1M in Q4 2016. 1,320 funds tracked by Wall St. Rank hold EW as of Q4 2021.

EULAV Asset Management reported no remaining Edwards Lifesciences position as of Q4 2021 after selling out during the quarter.
EULAV Asset Management sold 113,010 Edwards Lifesciences shares in Q4 2021, an estimated $12.8M.
EULAV Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and held it in 31 quarters.
EULAV Asset Management's Edwards Lifesciences position peaked at $16.1M in Q4 2016.
1,320 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on EULAV Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.